LHRH agonist

Luteinizing hormone releasing hormone (LHRH) agonist

A substance that blocks the action of LHRH, a hormone that stimulates the production of testosterone (a male hormone) in men. Used to treat prostate cancers that require testosterone for growth.
Mentioned in: Prostate Cancer
References in periodicals archive ?
LHRH agonist, abiraterone, Enzalutamide, oestrogens, ketoconazole, and steroids along with supportive care must accompany treatment.
19,20,22,23) In a population-based series of 1442 men in Quebec undergoing LHRH agonist therapy with curative radiation therapy, the risk of any breakthrough during 2334 person-years of followup was 4.
Subjects receiving LHRH agonist therapy complained of a plethora of symptoms.
It is the only LHRH agonist available via subcutaneous injection with the innovative, controlled release ATRIGEL Delivery System.
Characteristics of luteinizing hormones (LH) and testosterone secretion, pituitary responses to LH-releasing hormone (LHRH), and reproductive function in young bulls receiving the LHRH agonist deslorelin: effect of castration on LH responses to LHRH.
Key products include Ferrlecit, an intravenous iron for use in the dialysis setting; Trelstar, an LHRH agonist for treating advanced prostate cancer; Androderm, a transdermal patch for testosterone replacement therapy in men; and Oxytrol, a transdermal patch for treating overactive bladders.
It is not possible to assign menopausal status to women receiving an LHRH agonist or antagonist, the guidelines state.
Medroxyprogesterone acetate is not an antiandrogen per se but is, rather, a progestational agent that reduces testosterone levels indirectly Leuprolide acetate, an LHRH agonist, has a comparable effect and has been effective in patients who did not respond to medroxyprogesterone acetate and other agents.
Long term reversible suppression of estrus in bitches with nafarelin acetate, a potent LHRH agonist.
An LHRH agonist is made in the laboratory; it is like LHRH but has a different effect on the body's functions.
LHRH agonist therapy is standard of care for suitable patients in both the neo-adjuvant and adjuvant setting to radiotherapy for curative intent in prostate cancer.
According to a published report, just 30% of the delegates of the European Association of Urology agreed with the EAU's recommendation to use radiotherapy in combination with adjuvant hormone therapy for men with T3-T4 prostate cancer, whereas 48% said that they would prescribe LHRH agonist monotherapy (Eur.